2015 Symposia

Monday 2 November 2015

Big data

Benchmarking and biomarkers: the molecular and technical heterogeneity of prostate cancer
Molecular archaeology of cancer
Understanding genome organisation:using HiC data to interpret gene regulation and non-coding mutations

Chromatin, epigenetics and cancer

Introduction: Chromatin, epigenetics and cancer
Epigenetic targets for cancer drug discovery: bromodomains and beyond
Epigenetic reprogramming in mammalian development
Epigenetics impacts copy number heterogeneity and drug resistant gene selection

Immunotherapy

Gut microbiota and anti-cancer immune responses
The mechanistic basis of cancer immunotherapy
T cells and the immunogenicity of immunotherapy

Molecular testing in cancer screening: ready for prime time

Working together in the genomics era: lessons from the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study
Molecular biomarkers: are they so much better than traditional risk factors and simple biomarkers?
Devising the ideal test for early diagnosis of cancer: lessons from the oesophagus

Tuesday 3 November 2015

DNA repair and cancer

Protective packaging for DNA: the role of the PBAF and INO80 chromatin remodelling complexes in maintaining genome stability
Role of the BRCA1:BARD1 ubiquitin ligase activity in DNA repair
Genetic dissection of tumour development, therapy response and resistance in mouse models of BRCA1-deficient breast cancer

Genomics and cancer evolution

Phylogenetic analysis reveals divergent modes of clonal spread and intraperitoneal mixing in high grade serous ovarian cancer
Evolution and drug resistance in cancer
Tracking tumour evolution with clonal assays: mutation order matters

Lifestyle behaviour and cancer prevention

Introduction: Lifestyle behaviour and cancer prevention
How many cancers can we prevent through dietary modifications?
Reducing exposure to alcohol to reduce cancer risk
Physical activity, obesity and cancer

Molecular imaging and radionuclide therapy

Molecularly targeted radiation therapy: towards individualised treatment
Translating novel diagnostic and therapeutic radiopharmaceuticals into the clinic
Radium-223 for prostate cancer bone metastases: how research can change clinical practice